<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541904</url>
  </required_header>
  <id_info>
    <org_study_id>LVO1209FII</org_study_id>
    <secondary_id>PRO-118</secondary_id>
    <nct_id>NCT01541904</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis</brief_title>
  <acronym>PRO-118</acronym>
  <official_title>STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRO-118 OPHTHALMIC SOLUTION IN ALLERGIC CONJUNCTIVITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of four doses of PRO-118
      ophthalmic solution ophthalmic solution compared with placebo, for the treatment of seasonal
      (SAC) and perennial (PAC) allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II, double-masked, randomized, placebo-controlled, parallel-group and multicenter
      clinical trial, to evaluate and compared the clinical efficacy and safety of four doses of
      PRO-118 ophthalmic solution ( PRO-118 0.015% qd, PRO-118 0.015% twice daily , PRO-118 0.020%
      qd, PRO-118 0.020% twice daily) for the treatment of seasonal (SAC) and perennial (PAC)
      allergic conjunctivitis.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Reformulation
  </why_stopped>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PRO-118 ophthalmic solution.</measure>
    <time_frame>21 days.</time_frame>
    <description>Primary efficacy measure: Evaluation of ocular itching.
Secondary efficacy measures: Evaluation of symptoms(redness eye,ocular irritation, foreign body sensation, photophobia and lacrimation) and signs(conjunctival hyperaemia,chemosis, mucous discharge ocular and presence of follicles/papillae).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of PRO-118 Ophthalmic Solution.</measure>
    <time_frame>21 days.</time_frame>
    <description>Evaluation of ocular symptoms and signs, visual acuity (VA), biomicroscopy, intraocular pressure (IOP), funduscopy and cup disc-ratio.
Frequency, severity and relationship to study medication of all adverse events occurring during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Ocular Itching</condition>
  <condition>Ocular Allergy</condition>
  <condition>Seasonal Allergic Conjunctivitis</condition>
  <condition>Perennial Allergic Conjunctivitis</condition>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>Arm A. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E PRO-118/Placebo 0.015%,0.020%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-118 Ophthalmic Solution 0.015%</intervention_name>
    <description>PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days</description>
    <arm_group_label>Arm A. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-118 Ophthalmic Solution 0.015 %</intervention_name>
    <description>PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days</description>
    <arm_group_label>Arm B. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-118 Ophthalmic Solution 0.020 %</intervention_name>
    <description>PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days</description>
    <arm_group_label>Arm C. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-118 Ophthalmic Solution 0.020 %</intervention_name>
    <description>PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days</description>
    <arm_group_label>Arm D. PRO-118/Placebo 0.015%,0.020%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <description>Placebo Ophthalmic Solution applied qd during 21 days</description>
    <arm_group_label>Arm E PRO-118/Placebo 0.015%,0.020%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of seasonal or perennial allergic conjunctivitis.

          -  Age ≥ 6 years old at screening visit.

          -  Male or female patients.

        Applicable in patients ≥ 18 years old.

          -  Patient has signed the Informed Consent Form (ICF) prior to any screening procedures.

        Applicable in patients with age ≤ 18 years old.

          -  Patients Patients'parents or legal guardians signed an Informed Consent Form (ICF).

          -  The patients also provided written assent.

        Exclusion Criteria:

          -  Presence of any form of allergic conjunctivitis other than seasonal or perennial
             allergic conjunctivitis (Atopic keratoconjunctivitis, giant papillary conjunctivitis).

          -  Any other ophthalmic medication within seven days prior to randomization.

          -  Patient with one blind eye.

          -  Visual acuity of 20/40 in any eye.

          -  Patients with history of active stage of any other concomitant ocular disease.

          -  Contraindications or sensitivity to any component of the study treatments.

          -  Contact lens users.

          -  Ocular surgery within the past 3 months.

          -  Women who were not using an effective means of contraception or who were pregnant or
             nursing.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.

        Discontinuation criteria:

          -  Patients could be discontinued before the completion of the study because of use of
             prohibited medications, adverse events, pregnancy, protocol violations, lack of
             efficacy, or administrative reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María C Jiménez-Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Instituto de Oftalmología Fundación Conde de Valenciana, I.A.P.&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Concepción Santacruz-Valdés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Instituto de Oftalmología Fundación Conde de Valenciana, I.A.P.&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emma T Villaseñor-Fierro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miriam Becerra-Cotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leopoldo M Baiza-Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department. Laboratorios Sophia SA de CV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;Instituto de Oftalmología Fundación Conde de Valenciana, I.A.P</name>
      <address>
        <city>México, D.F.</city>
        <state>D.f.</state>
        <zip>06800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Allergy.</keyword>
  <keyword>Seasonal Allergic Conjunctivitis</keyword>
  <keyword>Perennial Allergic Conjunctivitis</keyword>
  <keyword>Conjunctivitis, Allergic</keyword>
  <keyword>Ocular Antihistamines.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

